HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Perfluorotripropylamine

HCID 67645
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
338-83-0
Standard SMILES
FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F
InChIKey
JAJLKEVKNDUJBG-UHFFFAOYSA-N
Molecular formula
N(C3F7)3
Average molar mass
521.07 g/mol
Monoisotopic mass
520.9695404

Overview

Perfluorotripropylamine is an organofluorine compound. It has a role as a blood substitute. It is functionally related to a tripropylamine.

Names & identifiers

Preferred name
Perfluorotripropylamine
IUPAC
1,1,2,2,3,3,3-heptafluoro-N,N-bis(1,1,2,2,3,3,3-heptafluoropropyl)propan-1-amine
English name
Perfluorotripropylamine
Molecular formula
C9F21N
Molecular weight
521.07

Names & synonyms

PerfluorotripropylaminePerfluamine338-83-0perfluorotri-n-propylamine1-Propanamine, 1,1,2,2,3,3,3-heptafluoro-N,N-bis(heptafluoropropyl)-HeneicosafluorotripropylamineFTPADTXSID90598343T396UK091Heptafluoro-N,N-bis(heptafluoropropyl)-1-propanamineCHEBI:38850RefChem:171630
Show more names
Perfluoro-tri-n-propylaminePFTPAXP-3288BofluoramineuorotripropyLPerfluoropropylaminePerfluoroamine TUW-3283
DTXCID0038752206-420-2Tris(perfluoropropyl)aminePerfluamina1,1,2,2,3,3,3-heptafluoro-N,N-bis(1,1,2,2,3,3,3-heptafluoropropyl)propan-1-amine1,1,2,2,3,3,3-Heptafluoro-N,N-bis(1,1,2,2,3,3,3-heptafluoropropyl)-1-propanamineMFCD00042589FLUOSOL DA PERFLUOROTRIPROPYLAMINE

Database identifiers

CAS
338-83-0
PubChem CID
67645
DTXSID
DTXSID9059834
ChEMBL
CHEMBL2104877
ChEBI
CHEBI:38850
UNII
3T396UK091
EC Number
206-420-2
Nikkaji
J191.935K

Properties

Computed structural propertiesFilling in

XLogP
7.9
Topological polar surface area
3.2 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
22
Rotatable bonds
6
Heavy atoms
31
Formal charge
0
Complexity
555

Experimental & physicochemical properties

PFAS · 6 items

PFAS -> Other/unspecified

PFAS -> OECD Category

PFAS -> Other Nonpolymers

PFAS -> Other/unspecified

PFAS -> non-polymer

PFAS -> PFAS with analytical method available

SpringerMaterials PropertiesSchoenflies notation
Density1.822 25 °C/4 °C
Boiling Point130 °C
Vapor Pressure20 mm Hg @ 37 °C
Refractive IndexIndex of refraction: 1.279 @ 25 °C
Other Experimental PropertiesPour point: -52 °C /from table/

Physicochemical properties

Melting point
-52 °C · -52 °C
Boiling point
125 · 125-135°C
Density
1.82 · 1.82
vapor pressure
5.16 hPa · 5.16hPa at 20℃
refractive index
1.279 · 1.279
storage temp.
-20 °C, · -20°C, Inert atmosphere
solubility
DMSO (Slightly), Methanol (Slightly), Water (Slightly)
pka
-27.02 · -27.02±0.50(Predicted)
form
Oil
color
Colourless
InChI
InChI=1S/C9F21N/c10-1(11,4(16,17)18)7(25,26)31(8(27,28)2(12,13)5(19,20)21)9(29,30)3(14,15)6(22,23)24
InChIKey
JAJLKEVKNDUJBG-UHFFFAOYSA-N
SMILES
C(F)(F)(N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)F
LogP
5.3 · 5.3-6.1
Substances of Very High Concern (SVHC) Candidate List
Perfluamine (338-83-0)
CAS DataBase Reference
338 · 338-83-0(CAS DataBase Reference)
FDA UNII
3 T396UK091 · 3T396UK091
NIST Chemistry Reference
1 · 1-Propanamine, 1,1,2,2,3,3,3-heptafluoro-N,N-bis(heptafluoropropyl)-(338-83-0)
EPA Substance Registry System
1 · 1-Propanamine, 1,1,2,2,3,3,3-heptafluoro-N,N-bis(heptafluoropropyl)- (338-83-0)
UNSPSC Code
12352116 · 12352116
NACRES
21 · NA.21
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
300 · H300-H317-H402
Precautionary statements
501 · P501-P261-P273-P272-P270-P264-P280-P302+P352-P362+P364-P333+P313-P301+P310+P330-P405
Hazard Codes
Xi
Risk Statements
36 · 36/37/38
Safety Statements
26 · 26-36
RIDADR
2735 · UN2735
WGK Germany
3 · WGK 3
Hazard Note
Irritant
TSCA
TSCA listed
HazardClass
8 · 8
HS Code
2921199990 · 2921199990
Storage Class
10 · 10 - Combustible liquids
Hazardous Substances Data
338 · 338-83-0(Hazardous Substances Data)
REACH Registrations
Active
Limited Quantities
5 L · 5.0 L (1.3 gallons) (liquid) or 5.0 kg (11 lbs) (solid)
Excepted Quantities
Max Inner Pack (30g or 30ml) and Max Outer Pack (1Kg or 1L)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 55.6% (5 of 9) of all reports.

Danger

H302 (44.4%): Harmful if swallowed [Warning Acute toxicity, oral]

P262, P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P316, P321, P330, P337+P317, P361+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 9 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 3 items

Hazard Traits - Bioaccumulation; Environmental Persistence

REACH registered substance: Perfluamine (EC: 206-420-2)

Substance: Perfluamine

Special Reports · 1 item

A review is presented of the chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, dosage and administration of Fluosol, a combination of perfluamine (perfluorotripropylamine) and perflunafene (perfluorodecalin) for use in the delivery of oxygen to ischemic myocardium during percutaneous transluminal coronary angioplasty.[Garrelts JC; DICP Ann. Pharmacother 24: 1105-12 (1990O]

Hazard Classes and CategoriesAcute Tox. 4 (44.4%)

Safety & protection

Disposal Methods · 1 item

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Toxicology

Non-Human Toxicity Excerpts · 5 items

/LABORATORY ANIMALS: Acute Exposure/ Using the hepatic macrophage system of the rat, cell alteration was examined by magnetometry after intravenous application of various perfluorochemicals (emulsified perfluorodecalin (C10F18), perfluorooctane (C8F17Br) and Fluosol-DA (corresponding to a 20% emulsion of 70% perfluorodecalin and 30% perfluorotripropylamine, C9F21N)). After administration of high doses, all perfluorochemicals led to cytoskeleton alteration. This alteration, expressed as retardation of the relaxation period of ferromagnetic iron oxide particles, was most pronounced after administration of Fluosol-DA.

/LABORATORY ANIMALS: Acute Exposure/ The effect of an emulsion of perfluorochemicals (PFC) (7 parts perfluorodecalin and 3 parts perfluorotripropylamine, 4.4 g PFC/kg bw) on organ function was determined. Whereas maximal storage of PFC was reached in the spleen as early as 12 hr after PFC administration, the liver attained a maximal PFC content only after 2 days. The increase in weight also differed: a maximum occurred in the spleen on the 4th day, in the liver on the 8th day. Indocyanine green (ICG) clearance showed a small decrease, statistically significant after 12 and 24 hr. Colloidal carbon clearance, used as a measure of the function of the reticuloendothelial system (RES) decreased instantly after PFC to less than half the control value; after full recovery a second decrease was seen which lasted till the 4th day after PFC. Pretreatment with C 48/80 or with increasing doses of E. coli endotoxin could largely obviate the depressive effect of PFC-loading on carbon clearance. Serum transaminases increased to about twice the control levels but were normal by the 2nd day, and thereafter. Alkaline phosphatase showed a 2.5 fold increase but returned to control level after the 2nd day. It is concluded that while a severe disturbance of liver function did not occur, the reduction in the capacity of the RES can become a serious factor in the defense against a simultaneously appearing infection if not compensated by activating the RES. /Perfluoro chemical emulsion/

/LABORATORY ANIMALS: Acute Exposure/ Because of uncertainty about the mechanism by which fluorocarbons ameliorate myocardial ischemia, the effects of a fluorocarbon emulsion, perfluorodecalin and perfluorotripropylamine (Fluosol-DA 20% TM) with and without 100% O2 inhalation, on cardiac hemodynamics and energetics were studied in the anesthetized dog. Left ventricular (LV) intramural partial pressure of oxygen (PmO2) was measured by before and after iv infusion of Fluosol-DA 20% (40 ml/kg), and was compared with measurements made in another group of dogs receiving the volume expander dextran (36 ml/kg). Both groups of dogs were then ventilated with 100% O2 and repeat measurements were performed. In the 11 animals receiving fluorocarbons, there were increases in left atrial pressure, LV myocardial blood flow, and LV myocardial O2 consumption (MVO2) compatible with volume expansion. After 100% O2, LV MVO2 decreased to control values, while PmO2 increased to 127 +/- 48 mm Hg (p<0.001). There were no significant changes in heart rate, arterial pressure or first derivative of LV pressure (dP/dt) during the study. In 10 dogs treated with dextran there was no change in heart rate or dP/dt, but arterial and left atrial pressures were higher after dextran infusion and remained elevated after 100% O2 inhalation. LV MVO2 increased with volume expansion, and remained increased after 100% O2. PmO2 (66 +/- 18 mm Hg) after 100% O2 was lower (p<0.02) than in the fluorocarbon-treated dogs after O2 inhalation.

Safety data

wgk
WGK 3
tsca
TSCA listed
ridadr
UN2735
hs_code
2921199990
risk_code
36/37/38
Signal word
Danger
Symbol(GHS)
GHS06
hazard_code
Xi
hazard_note
Irritant
safety_code
26-36
hazard_class
8
Storage Class
10 - Combustible liquids
Hazard statements
H300-H317-H402
Limited Quantities
5.0 L (1.3 gallons) (liquid) or 5.0 kg (11 lbs) (solid)
Excepted Quantities
Max Inner Pack (30g or 30ml) and Max Outer Pack (1Kg or 1L)
REACH Registrations
Active
Precautionary statements
P501-P261-P273-P272-P270-P264-P280-P302+P352-P362+P364-P333+P313-P301+P310+P330-P405
Hazardous Substances Data
338-83-0(Hazardous Substances Data)

Chemistry & industry

Pharmacology

Biological Half-Life · 2 items

Organ retention of the blood substitute component, perfluorotripropylamine (FTPA)... /was examined/. Various dosages of an emulsion of FTPA were administered to five rats. At intervals up to 86 weeks after infusion, (19F) MRI was used to measure the amount of FTPA in liver and spleen. The data were fit to both linear and exponential elimination models, and organ retention half-lives were calculated. The exponential half-lives for combined liver and spleen FTPA ranged from 110 to 190 days. Linear half-lives ranged from 175 to 300 days.

/In anemic patients/ the half-life of /fluosol-DA/ was 24.3+-4.3 hr.

Absorption, Distribution and Excretion · 2 items

The decline of the concentration of perfluorochemicals (PFC) after a single injection of three different doses was studied in the circulation of rats. The doses used amounted to 4.4, 10 and 14 g/kg body weight of Fluosol-DA, an emulsion of 7 parts of perfluorodecalin (FDC) and 3 parts of perfluorotripropylamine (FTPA). This also allowed testing of the composition of the emulsion remaining in the circulation and of that found in the liver. After two days a decrease of the half life from 34.0 +/- 0.7 to 17.1 +/- 4.3 h was found within the circulation at the highest dose. At the same time a change in the composition of the emulsion in the blood stream occurred, favouring the fraction of FTPA. FTPA increased from 28.3 +/- 1.4 to 54.4 +/- 8.1% on the fourth day. Whereas in the cells of the liver PFC droplets may be broken up, freed from their surfactant layer and handled according to their individual components, for PFC in the blood stream an unchanged composition should be assumed. Both results, the decreasing half life and the change in composition of the circulating emulsion may best be explained by a shrinking and instability of the emulgator film, showing the necessity for development of a superior surfactant. /Fluosol-DA/

The effect of an emulsion of perfluorochemicals (PFC) (7 parts perfluorodecalin and 3 parts perfluorotripropylamine, 4.4 g PFC/kg body weight) on organ function was determined. Whereas maximal storage of PFC was reached in the spleen as early as 12 h after PFC administration, the liver attained a maximal PFC content only after 2 days.

Uses & manufacturing

Uses · 4 items

The electronics industry relies heavily on these fluids in reliability testing of electronic components, as direct-contact coolants for integrated circuits, and as heating media in vapor-phase reflow soldering. /Fluorinated Tertiary Amines/

Blood substitute

non-polymer PFAS -> Biotechnology -> Supply of oxygen and other gases to cells in culture

• Supply of gases, including CO2, to microbial cells [Ref: https://doi.org/10.1007/978-1-4899-1202-2]

Methods of ManufacturingElectrochemical fluorination via the Simons process is the preferred route to fluorinated tertiary alkylamines. The hydrogen atoms are completely replaced by the fluorine atoms. /Fluorinatd Tertiary Amines/
Formulations/PreparationsFluosol-DA (20%), an emulsified mixture of perfluorodecalin and perfluorotripropylamine.
Use Classification · 2 items

PFAS -> PFalkylamine

PFAS (per- and polyfluoroalkyl substances) -> OECD Category

General Manufacturing Information1-Propanamine, 1,1,2,2,3,3,3-heptafluoro-N,N-bis(1,1,2,2,3,3,3-heptafluoropropyl)-: ACTIVE

Applications

UsesPerfluorotripropylamine is a reagent used in the surface modification of droplet polymeric microfluidic devices. This is used to improve the stable and continueous generation of aqueous droplets.

Additional notes

DefinitionChEBI: Perfluorotripropylamine is an organofluorine compound. It has a role as a blood substitute. It is functionally related to a tripropylamine.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

/LABORATORY ANIMALS: Acute Exposure/ IV administration of emulsions of some perfluorochemicals (PFCs) are followed by lung gas-exchange alterations, lung inflation and animal death. The emulsion toxicity can be caused by both low aggregation stability of the emulsion in the blood stream and appearance of the additional gas pressure in alveoli as a result of difference in the rates of alveolar gas and PFC vapor diffusion. Theoretical and experimental analysis shows that absence of emulsion particle aggregation into blood stream, low pressure of saturated vapors of PFC phase and relatively low rate of PFC expiration from the organism are essential conditions for the creation of a safe fluorocarbon blood substitutes.

For more Non-Human Toxicity Excerpts (Complete) data for PERFLUAMINE (6 total), please visit the HSDB record page.

Antidote and Emergency Treatment · 2 items

Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poison A and B/

Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in respiratory arrest. Positive pressure ventilation techniques with a bag valve mask device may be beneficial. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of fluid overload. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poison A and B/